| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Music | 3 | 2024 | 28 | 1.540 |
Why?
|
| Housing | 3 | 2024 | 74 | 1.400 |
Why?
|
| American Public Health Association | 2 | 2022 | 2 | 1.360 |
Why?
|
| Vulnerable Populations | 2 | 2026 | 166 | 1.030 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2026 | 95 | 0.870 |
Why?
|
| Education, Medical | 1 | 2026 | 118 | 0.860 |
Why?
|
| Primary Health Care | 2 | 2025 | 380 | 0.850 |
Why?
|
| Students, Medical | 1 | 2026 | 158 | 0.810 |
Why?
|
| Mental Disorders | 3 | 2025 | 392 | 0.810 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 115 | 0.800 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2023 | 6 | 0.790 |
Why?
|
| Computational Biology | 4 | 2024 | 327 | 0.790 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2023 | 20 | 0.780 |
Why?
|
| Zebrafish | 2 | 2021 | 146 | 0.770 |
Why?
|
| Atrial Fibrillation | 2 | 2025 | 122 | 0.750 |
Why?
|
| Single-Payer System | 1 | 2022 | 1 | 0.750 |
Why?
|
| Software | 1 | 2024 | 236 | 0.740 |
Why?
|
| Stroke | 3 | 2025 | 340 | 0.730 |
Why?
|
| Humans | 54 | 2026 | 43102 | 0.710 |
Why?
|
| Fundulidae | 2 | 2018 | 7 | 0.700 |
Why?
|
| Virus Diseases | 1 | 2021 | 27 | 0.680 |
Why?
|
| Uveal Neoplasms | 2 | 2019 | 11 | 0.660 |
Why?
|
| Mental Health | 1 | 2025 | 385 | 0.650 |
Why?
|
| Gills | 2 | 2018 | 14 | 0.610 |
Why?
|
| Salinity | 2 | 2018 | 19 | 0.610 |
Why?
|
| Melanoma | 2 | 2019 | 110 | 0.600 |
Why?
|
| Public Policy | 1 | 2019 | 36 | 0.600 |
Why?
|
| Osmotic Pressure | 1 | 2018 | 22 | 0.580 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 749 | 0.550 |
Why?
|
| Middle Aged | 23 | 2026 | 12222 | 0.550 |
Why?
|
| MicroRNAs | 4 | 2018 | 518 | 0.550 |
Why?
|
| Arsenic | 2 | 2018 | 155 | 0.520 |
Why?
|
| Brachytherapy | 1 | 2016 | 11 | 0.520 |
Why?
|
| Anticoagulants | 3 | 2025 | 122 | 0.510 |
Why?
|
| Depression | 1 | 2024 | 863 | 0.510 |
Why?
|
| Anxiety | 1 | 2024 | 874 | 0.490 |
Why?
|
| Adult | 19 | 2025 | 13872 | 0.480 |
Why?
|
| Aged | 21 | 2026 | 8214 | 0.480 |
Why?
|
| Male | 32 | 2026 | 23409 | 0.480 |
Why?
|
| Female | 32 | 2026 | 24698 | 0.470 |
Why?
|
| Aged, 80 and over | 12 | 2026 | 2853 | 0.470 |
Why?
|
| Inflammation | 1 | 2021 | 758 | 0.460 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 1070 | 0.440 |
Why?
|
| Retrospective Studies | 6 | 2025 | 2544 | 0.410 |
Why?
|
| Toxicogenetics | 3 | 2016 | 4 | 0.360 |
Why?
|
| Hemorrhage | 2 | 2021 | 55 | 0.340 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2026 | 497 | 0.330 |
Why?
|
| Thrombosis | 2 | 2021 | 81 | 0.320 |
Why?
|
| Treatment Outcome | 4 | 2023 | 1604 | 0.290 |
Why?
|
| Risk Factors | 5 | 2025 | 3994 | 0.290 |
Why?
|
| Texas | 5 | 2025 | 457 | 0.270 |
Why?
|
| Databases, Genetic | 3 | 2016 | 103 | 0.270 |
Why?
|
| Cause of Death | 2 | 2025 | 186 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2026 | 760 | 0.260 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 278 | 0.260 |
Why?
|
| Fish Proteins | 2 | 2018 | 16 | 0.250 |
Why?
|
| United States | 8 | 2026 | 5205 | 0.240 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2026 | 27 | 0.240 |
Why?
|
| Immunologic Memory | 1 | 2026 | 42 | 0.240 |
Why?
|
| Communicable Disease Control | 2 | 2023 | 38 | 0.240 |
Why?
|
| Choroid Neoplasms | 1 | 2025 | 1 | 0.240 |
Why?
|
| Osteotomy | 1 | 2025 | 4 | 0.240 |
Why?
|
| Hip Prosthesis | 1 | 2025 | 8 | 0.240 |
Why?
|
| Device Removal | 1 | 2025 | 7 | 0.240 |
Why?
|
| Choroid | 1 | 2025 | 11 | 0.240 |
Why?
|
| Reoperation | 1 | 2025 | 34 | 0.240 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2025 | 21 | 0.230 |
Why?
|
| Insurance Coverage | 2 | 2025 | 110 | 0.230 |
Why?
|
| Problem-Based Learning | 1 | 2026 | 42 | 0.230 |
Why?
|
| United States Environmental Protection Agency | 1 | 2025 | 6 | 0.230 |
Why?
|
| Power Plants | 1 | 2025 | 5 | 0.230 |
Why?
|
| Diabetes Complications | 1 | 2026 | 102 | 0.230 |
Why?
|
| B-Lymphocytes | 1 | 2026 | 189 | 0.220 |
Why?
|
| Postoperative Complications | 2 | 2025 | 263 | 0.220 |
Why?
|
| Quality of Health Care | 1 | 2026 | 161 | 0.220 |
Why?
|
| Health Care Costs | 1 | 2025 | 91 | 0.220 |
Why?
|
| Sparrows | 1 | 2024 | 4 | 0.210 |
Why?
|
| DNA | 2 | 2019 | 592 | 0.210 |
Why?
|
| Conserved Sequence | 1 | 2024 | 122 | 0.210 |
Why?
|
| Secondary Prevention | 2 | 2025 | 48 | 0.210 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 112 | 0.210 |
Why?
|
| DNA Transposable Elements | 1 | 2024 | 55 | 0.210 |
Why?
|
| Occupational Diseases | 1 | 2024 | 53 | 0.210 |
Why?
|
| Data Collection | 1 | 2024 | 210 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2025 | 145 | 0.210 |
Why?
|
| Factor Analysis, Statistical | 1 | 2024 | 162 | 0.200 |
Why?
|
| Time Factors | 5 | 2025 | 1857 | 0.200 |
Why?
|
| Young Adult | 7 | 2025 | 5080 | 0.200 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 20 | 0.200 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2023 | 10 | 0.200 |
Why?
|
| Aorta, Abdominal | 1 | 2023 | 17 | 0.200 |
Why?
|
| Radiation Oncology | 1 | 2022 | 2 | 0.200 |
Why?
|
| Curriculum | 1 | 2026 | 318 | 0.200 |
Why?
|
| Mortality | 1 | 2024 | 175 | 0.190 |
Why?
|
| Morbidity | 1 | 2023 | 97 | 0.190 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2024 | 171 | 0.190 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2024 | 188 | 0.190 |
Why?
|
| Coloring Agents | 1 | 2022 | 55 | 0.190 |
Why?
|
| Reproducibility of Results | 3 | 2025 | 1081 | 0.190 |
Why?
|
| Insurance Carriers | 1 | 2022 | 2 | 0.190 |
Why?
|
| Kidney Diseases | 1 | 2024 | 172 | 0.180 |
Why?
|
| Animals | 11 | 2024 | 16992 | 0.180 |
Why?
|
| Health Care Reform | 1 | 2022 | 36 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2020 | 47 | 0.180 |
Why?
|
| Age Factors | 1 | 2025 | 1154 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2026 | 719 | 0.170 |
Why?
|
| Factor Xa | 1 | 2021 | 4 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2021 | 44 | 0.170 |
Why?
|
| Infection Control | 1 | 2021 | 18 | 0.170 |
Why?
|
| Peptide Fragments | 1 | 2023 | 307 | 0.170 |
Why?
|
| Cultural Diversity | 1 | 2022 | 193 | 0.170 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 28 | 0.170 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 259 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2023 | 231 | 0.160 |
Why?
|
| Physicians | 1 | 2023 | 188 | 0.160 |
Why?
|
| Alcoholism | 1 | 2024 | 305 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2026 | 495 | 0.160 |
Why?
|
| Phenotype | 5 | 2026 | 780 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 38 | 0.160 |
Why?
|
| Immunity, Innate | 1 | 2021 | 171 | 0.160 |
Why?
|
| Homeostasis | 1 | 2021 | 192 | 0.160 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 61 | 0.150 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 518 | 0.150 |
Why?
|
| Human Rights | 1 | 2019 | 11 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 310 | 0.150 |
Why?
|
| Prospective Studies | 5 | 2023 | 1600 | 0.150 |
Why?
|
| Disease | 2 | 2016 | 21 | 0.150 |
Why?
|
| Ion Transport | 1 | 2018 | 23 | 0.150 |
Why?
|
| Body Height | 1 | 2019 | 53 | 0.150 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 88 | 0.150 |
Why?
|
| Acclimatization | 1 | 2018 | 25 | 0.140 |
Why?
|
| Leukopoiesis | 1 | 2018 | 1 | 0.140 |
Why?
|
| School Health Services | 1 | 2019 | 90 | 0.140 |
Why?
|
| Chemokine CXCL12 | 1 | 2018 | 32 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1067 | 0.140 |
Why?
|
| Hydrocarbons | 1 | 2017 | 4 | 0.140 |
Why?
|
| Methane | 1 | 2017 | 12 | 0.140 |
Why?
|
| Metagenomics | 1 | 2017 | 46 | 0.130 |
Why?
|
| Leukocytes | 1 | 2018 | 80 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2024 | 661 | 0.130 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 74 | 0.130 |
Why?
|
| Albuterol | 1 | 2017 | 7 | 0.130 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2017 | 22 | 0.130 |
Why?
|
| Bronchodilator Agents | 1 | 2017 | 26 | 0.130 |
Why?
|
| Body Weight | 1 | 2019 | 429 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 374 | 0.130 |
Why?
|
| Ecosystem | 1 | 2018 | 175 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 165 | 0.130 |
Why?
|
| Uvea | 1 | 2016 | 3 | 0.130 |
Why?
|
| Sclera | 1 | 2016 | 6 | 0.130 |
Why?
|
| Iodine Radioisotopes | 1 | 2016 | 38 | 0.130 |
Why?
|
| Evolution, Molecular | 2 | 2016 | 307 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 39 | 0.130 |
Why?
|
| Genome | 2 | 2016 | 149 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2019 | 189 | 0.130 |
Why?
|
| Psychometrics | 1 | 2019 | 358 | 0.130 |
Why?
|
| Search Engine | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tennessee | 1 | 2016 | 93 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 587 | 0.120 |
Why?
|
| Chlorogenic Acid | 1 | 2016 | 1 | 0.120 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 171 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2019 | 760 | 0.120 |
Why?
|
| Visual Acuity | 1 | 2016 | 111 | 0.120 |
Why?
|
| Ilex paraguariensis | 1 | 2016 | 5 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2018 | 141 | 0.120 |
Why?
|
| Lymphatic Metastasis | 2 | 2006 | 81 | 0.120 |
Why?
|
| Survival Rate | 1 | 2016 | 355 | 0.120 |
Why?
|
| Length of Stay | 1 | 2017 | 229 | 0.120 |
Why?
|
| Vertebrates | 1 | 2015 | 34 | 0.120 |
Why?
|
| Contrast Media | 2 | 2006 | 103 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 154 | 0.120 |
Why?
|
| Phylogeny | 2 | 2018 | 769 | 0.120 |
Why?
|
| Models, Genetic | 1 | 2016 | 183 | 0.110 |
Why?
|
| Plant Leaves | 1 | 2016 | 136 | 0.110 |
Why?
|
| Oxides | 2 | 2006 | 100 | 0.110 |
Why?
|
| Mammals | 1 | 2016 | 112 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2013 | 341 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2015 | 63 | 0.110 |
Why?
|
| Vietnam | 2 | 2025 | 62 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2019 | 925 | 0.110 |
Why?
|
| Placenta | 1 | 2016 | 117 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 704 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 863 | 0.110 |
Why?
|
| Iron | 2 | 2006 | 251 | 0.110 |
Why?
|
| Publications | 1 | 2013 | 10 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 30 | 0.100 |
Why?
|
| Drug Industry | 1 | 2013 | 18 | 0.100 |
Why?
|
| Adolescent | 6 | 2025 | 6081 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1078 | 0.100 |
Why?
|
| RNA | 1 | 2015 | 266 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 149 | 0.100 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 143 | 0.100 |
Why?
|
| Asthma | 1 | 2017 | 416 | 0.100 |
Why?
|
| Alopecia Areata | 1 | 2012 | 4 | 0.100 |
Why?
|
| Hair Follicle | 1 | 2012 | 12 | 0.100 |
Why?
|
| Neoplasms | 2 | 2022 | 1377 | 0.100 |
Why?
|
| Retinoids | 1 | 2012 | 25 | 0.090 |
Why?
|
| Lung | 1 | 2015 | 492 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 94 | 0.090 |
Why?
|
| Prognosis | 2 | 2026 | 861 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2026 | 1063 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2011 | 18 | 0.090 |
Why?
|
| Head Protective Devices | 1 | 2011 | 11 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 269 | 0.090 |
Why?
|
| Child | 5 | 2021 | 3443 | 0.090 |
Why?
|
| Craniocerebral Trauma | 1 | 2011 | 22 | 0.090 |
Why?
|
| Bicycling | 1 | 2011 | 18 | 0.090 |
Why?
|
| Mental Recall | 1 | 2011 | 84 | 0.090 |
Why?
|
| Purpura Fulminans | 1 | 2010 | 1 | 0.080 |
Why?
|
| Meningococcal Infections | 1 | 2010 | 4 | 0.080 |
Why?
|
| Peritonitis | 1 | 2010 | 11 | 0.080 |
Why?
|
| Neisseria meningitidis | 1 | 2010 | 17 | 0.080 |
Why?
|
| Crotalid Venoms | 1 | 2010 | 2 | 0.080 |
Why?
|
| Snake Bites | 1 | 2010 | 2 | 0.080 |
Why?
|
| Antivenins | 1 | 2010 | 4 | 0.080 |
Why?
|
| Brain Injuries | 1 | 2011 | 129 | 0.080 |
Why?
|
| ROC Curve | 3 | 2021 | 159 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 611 | 0.070 |
Why?
|
| Cytokines | 1 | 2010 | 678 | 0.060 |
Why?
|
| Prosthesis Failure | 1 | 2025 | 19 | 0.060 |
Why?
|
| Seawater | 2 | 2017 | 54 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 609 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2025 | 47 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3156 | 0.060 |
Why?
|
| Medicare Part C | 1 | 2026 | 18 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2006 | 74 | 0.060 |
Why?
|
| Femur | 1 | 2025 | 47 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2025 | 135 | 0.060 |
Why?
|
| Greenhouse Effect | 1 | 2025 | 5 | 0.060 |
Why?
|
| Efficiency, Organizational | 1 | 2025 | 15 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2025 | 65 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2017 | 1546 | 0.050 |
Why?
|
| Influenza A virus | 1 | 2024 | 31 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2024 | 32 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2024 | 68 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 76 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2025 | 179 | 0.050 |
Why?
|
| Comorbidity | 1 | 2026 | 737 | 0.050 |
Why?
|
| Trust | 1 | 2025 | 167 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2024 | 108 | 0.050 |
Why?
|
| Candida | 1 | 2023 | 42 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 58 | 0.050 |
Why?
|
| Microscopy | 1 | 2022 | 35 | 0.050 |
Why?
|
| Algorithms | 1 | 2025 | 509 | 0.050 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2022 | 17 | 0.050 |
Why?
|
| Mice | 3 | 2020 | 6644 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2024 | 515 | 0.050 |
Why?
|
| Social Isolation | 1 | 2022 | 34 | 0.050 |
Why?
|
| Cell Communication | 1 | 2023 | 114 | 0.050 |
Why?
|
| Loneliness | 1 | 2022 | 24 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 62 | 0.040 |
Why?
|
| Urinalysis | 1 | 2021 | 34 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2024 | 1180 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2023 | 169 | 0.040 |
Why?
|
| Candida albicans | 1 | 2023 | 176 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2021 | 54 | 0.040 |
Why?
|
| North America | 1 | 2021 | 85 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 115 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 153 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 27 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 152 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 293 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 260 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2021 | 78 | 0.040 |
Why?
|
| Health Personnel | 1 | 2023 | 277 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 375 | 0.040 |
Why?
|
| Suicide | 1 | 2021 | 140 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 6 | 0.040 |
Why?
|
| Pseudoxanthoma Elasticum | 1 | 2019 | 32 | 0.040 |
Why?
|
| Veterans | 1 | 2021 | 210 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 290 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 706 | 0.040 |
Why?
|
| Psychotropic Drugs | 1 | 2018 | 18 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 7 | 0.040 |
Why?
|
| Gender Identity | 1 | 2019 | 117 | 0.030 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 23 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 616 | 0.030 |
Why?
|
| Deltaproteobacteria | 1 | 2017 | 8 | 0.030 |
Why?
|
| Gammaproteobacteria | 1 | 2017 | 7 | 0.030 |
Why?
|
| Archaea | 1 | 2017 | 17 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 2157 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 863 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 195 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 174 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 690 | 0.030 |
Why?
|
| Counseling | 1 | 2018 | 138 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2020 | 638 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 155 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 800 | 0.030 |
Why?
|
| Ferrosoferric Oxide | 2 | 2006 | 13 | 0.030 |
Why?
|
| Dextrans | 2 | 2006 | 29 | 0.030 |
Why?
|
| Quinic Acid | 1 | 2016 | 3 | 0.030 |
Why?
|
| Caffeic Acids | 1 | 2016 | 5 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2016 | 74 | 0.030 |
Why?
|
| Students | 1 | 2022 | 626 | 0.030 |
Why?
|
| Fossils | 1 | 2016 | 14 | 0.030 |
Why?
|
| Food Handling | 1 | 2016 | 35 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 84 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 1035 | 0.030 |
Why?
|
| Alu Elements | 1 | 2015 | 12 | 0.030 |
Why?
|
| Genetic Speciation | 1 | 2016 | 24 | 0.030 |
Why?
|
| Guanosine | 1 | 2015 | 28 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 46 | 0.030 |
Why?
|
| Adenosine Deaminase | 1 | 2015 | 21 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2015 | 42 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 82 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2016 | 141 | 0.030 |
Why?
|
| RNA Editing | 1 | 2015 | 37 | 0.030 |
Why?
|
| Salts | 1 | 2014 | 18 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 541 | 0.030 |
Why?
|
| Fresh Water | 1 | 2014 | 48 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 75 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 1869 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1596 | 0.030 |
Why?
|
| Chemokine CXCL9 | 1 | 2012 | 3 | 0.020 |
Why?
|
| Tissue Banks | 1 | 2012 | 9 | 0.020 |
Why?
|
| Granzymes | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 80 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2012 | 20 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2012 | 41 | 0.020 |
Why?
|
| Animal Feed | 1 | 2012 | 53 | 0.020 |
Why?
|
| Vitamin A | 1 | 2012 | 86 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 177 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2011 | 20 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2011 | 21 | 0.020 |
Why?
|
| Radiography | 1 | 2011 | 71 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 269 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 113 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 162 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 236 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 128 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 48 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 183 | 0.020 |
Why?
|
| Agkistrodon | 1 | 2010 | 1 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 2010 | 7 | 0.020 |
Why?
|
| Crotalus | 1 | 2010 | 4 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2010 | 23 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2010 | 24 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 1772 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2010 | 70 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2010 | 75 | 0.020 |
Why?
|
| Peroxidase | 1 | 2010 | 57 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 575 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 667 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 587 | 0.020 |
Why?
|
| Health Promotion | 1 | 2016 | 704 | 0.020 |
Why?
|
| Skin | 1 | 2010 | 187 | 0.020 |
Why?
|
| HIV Infections | 1 | 2021 | 2586 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3735 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 440 | 0.010 |
Why?
|
| Nanoparticles | 1 | 2006 | 460 | 0.010 |
Why?
|